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INTRODUCTION
Myelodysplastic syndrome (MDS) comprises clonal
hematopoietic disorders that are associated with ineffective
hematopoiesis, peripheral cytopenias, and a tendency to
progress to acute myeloid leukemia (AML). The French-
American-British classiﬁcation system divides patients into
5 distinct pathologic groups [1-3]. However, additional forms
of MDS have also been recognized, including hypoplastic
MDS, MDS with myeloﬁbrosis, refractory cytopenias with
trilineage dysplasia, and aplastic anemia with clonal cytoge-
netic abnormality [4-7]. Most of these categories of MDS
make a distinction between patients with and without excess
marrow blasts (deﬁned as <5%) because of its dramatic impact
on prognosis. The International Prognostic Scoring System,
which uses a new classification system to provide refined
prognostic information, divides patients into 4 subgroups
based on percentages of marrow blasts, karyotype, and num-
ber of cytopenias [8]. Although many patients without excess
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ABSTRACT
Patients with the refractory anemia (RA) subtype of myelodysplastic syndrome who undergo allogeneic bone mar-
row transplantation (BMT) have a low risk of relapse, but they have a high risk of nonrelapse mortality when pre-
pared with conventional preparative regimens. To try to reduce nonrelapse mortality, we treated 14 RA patients
with a modified approach to total body irradiation (TBI) followed by cyclophosphamide (CY) and HLA-identical
sibling BMT. Median patient age was 44 years (range, 28 to 65 years). Patients received TBI with shielding of the
right lobe of the liver and both lungs followed by electron beam boosts to shielded ribs. Total radiation exposure in
nonshielded areas was 12 Gy (n = 10), 10 Gy (n = 3), or 6 Gy (n = 1). After TBI, patients received CY at 120 mg/kg
over 2 days, followed by transplantation of unmanipulated bone marrow. All patients initially achieved engraftment
with donor cells, although 2 patients had subsequent reemergence of host hematopoiesis without evidence of dis-
ease relapse. Five patients died of transplantation-related causes between 22 and 1262 days post-BMT. Four
patients relapsed between 157 and 1096 days post-BMT. These 14 patients were compared with 46 historical con-
trols with RA who received conventional CY/TBI or busulfan/CY preparative regimens. Patients in the experimen-
tal group had a similar nonrelapse mortality rate compared with the historical control group (29% versus 37%,
respectively; P = .8), but a higher relapse rate (34% versus 2%, P = .0004) and a lower disease-free survival (38%
versus 61%, P = .16). We conclude that this modified TBI approach is associated with an unacceptably high risk of
relapse for patients with RA undergoing BMT.
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blasts (ie, refractory anemia [RA]) have an indolent course,
those patients with 2 or more peripheral cytopenias and/or
intermediate- or poor-risk cytogenetic features have an inter-
mediate-1 or intermediate-2 International Prognostic Score
and an expected median survival of 1.2 to 3.5 years [8].
Allogeneic bone marrow transplantation (alloBMT) is
the only known curative therapy for MDS and is more suc-
cessful in patients with RA than for patients with RA with
excess blasts (RAEB) or RAEB in transformation (RAEB-T),
because of a lower relapse rate among patients without
increased blast counts [9-18]. We have previously reported
70 patients with RA who underwent alloBMT consecutively
between 1981 and 1993 after a preparative regimen of either
cyclophosphamide (CY) with total body irradiation (TBI) or
busulfan (BU)/CY [19]. In that study, there was no difference
in outcome between these preparative regimens. Overall, the
3-year disease-free survival (DFS) was 63%, the 3-year non-
relapse mortality was 37%, and of the 70 patients, only
1 relapsed [19]. Studies from other centers also demonstrate
a very low risk of relapse among RA patients who receive
conventional preparative regimens [9,10,13-15]. Beginning
in 1994, we prospectively studied a new preparative regimen
consisting of TBI with liver and lung shielding followed by
CY in RA patients undergoing human leukocyte antigen
(HLA)-identical, related-donor BMT. We hypothesized that
shielding these organs from radiation would improve DFS
by reducing the risk of nonrelapse mortality, without com-
promising the low risk of relapse. Here we describe the
results of 14 patients treated with this modiﬁed TBI regi-
men, in whom the cumulative incidence of relapse at 3 years
was 34%. This extraordinarily high rate of relapse appears to
be higher than expected based on historical control subjects
treated at our institution and other institutions, suggesting
that this treatment approach should not be pursued further.
PATIENTS AND METHODS
Between February 1994 and July 1996, all MDS patients
with <5% marrow blasts and ≤1% peripheral blood blasts
[2,4,6,7] who were referred to the Fred Hutchinson Cancer
Research Center or affiliated hospitals for HLA-matched,
related-donor BMT were enrolled on a single treatment
protocol. Patients with RAEB, RAEB-T, or chronic
myelomonocytic leukemia at or anytime before BMT, and
patients with RA undergoing BMT from unrelated or mis-
matched related donors were prospectively treated using
other transplantation protocols. In addition, patients with
features associated with extramedullary hematopoiesis (ie,
hepatomegaly, leukoerythroblastic peripheral blood smear,
or severe marrow fibrosis) were ineligible for the study.
Therapy-related MDS and/or prior allogeneic or autolo-
gous transplantation for an antecedent disease were not
exclusion criteria for study entry, similar to prior MDS
treatment protocols. Evaluation in Seattle immediately
before the preparative regimen included complete blood
count, bone marrow aspirate and biopsy, chromosomal
analysis of bone marrow cells, and HLA typing of donor and
recipient. Karyotypes were classiﬁed according to the IPSS
into low-, intermediate-, and poor-risk groups [8].
Prior to conditioning, each patient was evaluated in the
radiation oncology department and underwent simulation
and computed tomography–based treatment planning. Indi-
vidually customized cerrobend blocks were designed to shield
the majority of the lungs and the right lobe of the liver with
edges of 1.0 to 1.5 centimeters from the inner border of the
lateral ribs, the diaphragm, and the lateral aspects of the ver-
tebral bodies. The blocks were designed to absorb approxi-
mately 95% of the incident radiation. The ribs under the
blocks were then boosted through 4 separate direct electron
ﬁelds to bring these areas up to the prescribed dose. Patients
received fractionated TBI (2 Gy/fraction twice daily) deliv-
ered alternatively from the anterior and posterior directions
from a linear accelerator with an energy of 6 MV and a dose
rate of 12 cGy/min. Initially the protocol was designed for
all patients to receive 6 fractions of TBI, for a total exposure
of 12 Gy. One patient (UPN 8821), however, received only
6 Gy because of a dosimetry calculation error. Beginning in
June 1995, the protocol was modiﬁed to include a dose de-
escalation arm of TBI exposure for patients older than
55 years. Subsequently, 3 patients received a total exposure
of 10 Gy (UPN 9813, UPN 10819, UPN 10874). After
TBI, all patients received intravenous CY daily, 60 mg/kg
for 2 days (total dose, 120 mg/kg). Approximately 36 to
48 hours after completion of CY treatment, each patient
received an infusion of non–T-cell–depleted marrow from a
genotypically HLA-identical sibling. GVHD prophylaxis
consisted of methotrexate and either cyclosporine or FK506
[20,21]. The treatment protocol was approved by the Insti-
tutional Review Board and informed consent was obtained
from all patients before initiating therapy.
Historical control patients consisted of all consecutive
patients (n = 46) with RA who underwent alloBMT in Seattle
before 1994 from a genotypically HLA-identical sibling and
met the same study entry criteria as described above. These
patients have been reported in previous publications
[16,19,22]. Control patients received a preparative regimen of
BU (16 mg/kg)/CY (120 mg/kg) (n = 21) or CY (120 mg/kg)/
TBI (12 Gy, n = 24; 14 Gy, n = 1) without organ shielding
(n = 25) as previously described (16,19). TBI in these patients
was generally administered using a cobalt source at 6 to
7 cGy/min in 200 cGy daily fractions. We included histori-
cal control patients who received either BU/CY or CY/TBI,
because we have previously demonstrated that there is no
difference in nonrelapse mortality rate or relapse rate for
RA patients who receive either of these 2 preparative regi-
mens at our institution [19]. The median age of these
46 control patients was 32.7 years (range, 2.3-65.5 years).
The median time from diagnosis to BMT was 8 months
(range, 1-180 months). Five patients had therapy-related
MDS (due to prior treatment for Hodgkin’s disease (n = 3),
multiple myeloma (n = 1), and polycythemia vera (n = 1). At
time of BMT, 24 patients had a low-risk karyotype, 10 had an
intermediate-risk karyotype, 10 had a poor-risk karyotype,
and 2 had inadequate cytogenetic analysis. At time of BMT,
according to the IPSS, 1 patient was in the low-risk category,
34 were in the intermediate-1 category, 9 were in the inter-
mediate-2 category, and 2 were not evaluable.
The methods of time-to-event analysis were used with
date of last contact before August 1999 for patients who
remained at risk. Actuarial DFS estimates and curves were
calculated by Kaplan-Meier method [23]. Relapse and non-
relapse mortality estimates and curves were expressed as
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cumulative incidences [24]. Relapse was defined as either
recurrence of a previously observed cytogenetic abnormal-
ity, the presence of ≥5% marrow blasts, or the return of
morphologic dysplasia with peripheral cytopenias and
return of host hematopoiesis (≥5% host cells). Neutrophil
engraftment was defined as the first of 2 consecutive days
with an absolute neutrophil count of >0.5 × 109/L. Platelet
engraftment was defined as the first day with a platelet
count  of >50 × 109/L, without transfusion. Bone marrow
examinations were routinely performed at approximately
28 days, 80 days, 1 year after transplantation, and when
clinically indicated. Chimerism studies were performed in
sex-mismatched transplantations by fluorescence in situ
hybridization with a Y-chromosome–speciﬁc DNA probe using
Table 1. Clinical Characteristics of 14 Patients With Refractory Anemia Before Receiving the Modiﬁed CY/TBI Preparative Regimen*
Patient Age (y) Time From ANC PLT IPSS
Number and Sex Diagnosis to BMT Etiology Karyotype HCT, % (× 109/L) (× 109/L) at BMT
8217 43, M 4 mo Idiopathic del 5q, t(2;11) 23.1 4.400 298 Int-1
8315 43, F 45 mo Idiopathic t(2;3) 29.1 3.267 326 Int-1
8454 42, F 8 mo Idiopathic +6 30.5 1.250 6 Int-1
8587 36, M 20 mo Idiopathic Normal 28.2 1.078 90 Int-1
8821 62, M 10 mo Idiopathic Normal 24.3 1.125 104 Int-1
9075 28, M 2 mo History of Normal 26.0 0.912 7 Int-1
aplastic anemia
9403 32, M 3 mo Idiopathic Normal 24.3 0.432 13 Int-1
9589 49, M 8 mo Idiopathic Normal 16.0 0.396 15 Int-1
9594 52, M 3 mo Idiopathic Normal 28.7 0.192 104 Int-1
9813 64, F 19 mo Idiopathic del5q, del7q, inv12, 33.0 3.803 69 Int-1
del15q, invX, del7p,
–5, t(13;14), 
and others
10393 45, F 7 mo Therapy for t(5;17) 36.8 3.150 27 Int-1
breast cancer
10819 59, F 7 mo Idiopathic 5q– 28.6 3.126 293 Low
10874 65, M 44 mo Idiopathic Normal 25.0 0.066 39 Int-1
10889 42, F 34 mo Idiopathic Normal 33.8 0.594 9 Int-1
*CY/TBI indicates cyclophosphamide/total body irradiation; BMT, bone marrow transplantation; HCT, hematocrit; ANC, absolute neutrophil
count; PLT, platelet count; IPSS, International Prognostic Scoring System; del, deletion; t, translocation; inv, inversion. 
Table 2. Posttransplantation Outcome of 14 Patients With Refractory Anemia Who Received the Modiﬁed CY/TBI Preparative Regimen*
Patient ANC of PLT of Acute Chronic
Number >5 × 109† >50 × 109† GVHD GVHD Outcome
8217 NR NR No No Day 22, died RSV pneumonia
8315 Day 19 Day 20 No No Day 533, relapse (karyotype at relapse: complex, including t(2;3) and 
chromosome 7 abnormality), died of progressive disease after 
second BMT
8454 Day 16 Day 19 Grade II No Day 91, died of RSV and CMV pneumonia
8587 Day 19 Day 27 Grade II Yes Day 1856, alive and well
8821 Day 22 Day 36 Grade II Yes Day 309, died of infection and chronic GVHD
9075 Day 24 NR No No Day 1262 died of infection and chronic GVHD (had second BMT 
for graft failure)
9403 Day 19 Day 19 No No Day 1313, alive and well
9589 Day 24 Day 303 No No Day 1096, relapse (karyotype at relapse: not assessed), died of 
progressive disease
9594 Day 27 Day 29 No No Day 450, relapse (karyotype at relapse: t(2;6), add9p, +mars), alive 
and well after second BMT
9813 Day 27 Day 25 Grade II No Day 157, relapse (karyotype at relapse: same as pretransplantation), 
died of progressive disease
10393 Day 18 Day 28 Grade II No Day 57, died of pneumonitis
10819 Day 20 Day 20 No No Day 644, alive and well
10874 Day 24 Day 36 Grade II Yes Day 378, alive and well
10889 Day 22 Day 30 No No Day 655, alive and well
*CY/TBI indicates cyclophosphamide/total body irradiation; ANC, absolute neutrophil count; PLT, platelet count; GVHD, graft-versus-host
disease; NR, not reached; RSV, respiratory syncytial virus; BMT, bone marrow transplantation; CMV, cytomegalovirus.
†Day on which the threshold value of ANC or PLT were reached. 
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techniques previously described [25]. In sex-matched trans-
plantations, chimerism was assessed with the use of ampli-
ﬁed variable number of tandem repeat (VNTR) DNA mark-
ers, using at least 1 locus (including ApoB, D1S80, 33.6,
SE-33, 33.1, or YNZ22) according to previously published
methods [26,27]. The timing of chimerism studies was not
uniform, but they were generally performed, if possible, at
the time of a routine marrow examination or if clinically
indicated. Neither prophylactic nor preemptive donor lym-
phocyte infusions were administered to any patient prior to
cytogenetic or morphologic relapse. Univariable compar-
isons of the current patients with historical controls were
made using the Wilcoxon rank sum test for continuous vari-
ables (age, disease duration, and peripheral blood counts),
the chi-squared test for discrete variables, and the log rank
test for time-to-event variables [28].
RESULTS
Clinical characteristics of the 14 patients enrolled in this
study are shown in Table 1. Twelve patients had no known
cause for MDS. Of the remaining 2 patients, 1 (UPN 9075)
had a history of aplastic anemia, for which he received an
alloBMT 4 years earlier from the same HLA-identical sib-
ling after conditioning with CY alone. He subsequently
rejected the donor graft, reestablished host hematopoiesis,
and progressed into MDS. Another patient (UPN 10393)
had a history of stage III breast cancer for which she
received adjuvant CY and doxorubicin, chest wall irradia-
tion, chemotherapy mobilization of peripheral blood stem
cells (PBSC), and an autologous PBSC transplant after a
BU/CY preparative regimen. She was diagnosed with MDS
5 months after the autologous transplantation and 12 months
after starting treatment for breast cancer.
The posttransplantation outcome for these 14 patients is
shown in Table 2. Five patients died without clinical evi-
dence of relapse, primarily due to infection with or without
GVHD. Only 1 patient died of solid organ failure (pul-
monary), possibly due to toxicity of the preparative regimen
(UPN 10393). One patient (UPN 8217) died from infection
before engraftment. Among the remaining 13 patients, the
median time to neutrophil engraftment was 22 days (range,
16 to 27 days) and to platelet engraftment, 28 days (range,
19 days to “not-reached”).
Results of chimerism studies are shown in Table 3. All
13 patients who achieved engraftment had evidence for
≥95% donor hematopoiesis in the marrow at the ﬁrst time-
point evaluated. Two patients (UPN 8821 and 10393)
showed subsequent evidence of mixed chimerism (77% and
45% donor cells, respectively, in marrow sample), but with-
out morphologic evidence of relapse at time of death from
transplant-related causes. After achieving donor engraft-
ment, a third patient (UPN 9075) developed graft failure
with peripheral pancytopenia, 95% donor hematopoiesis,
and no morphologic evidence of dysplasia. This patient
subsequently underwent conditioning with an immunosup-
pressive regimen consisting of methylprednisolone and
monoclonal T-cell antibody (BC3) and allogeneic PBSC
infusion from his HLA-identical sibling. Although he
achieved sustained donor engraftment, he died on day 1262
from complications related to chronic GVHD.
Four patients relapsed between 157 days and 3 years
posttransplantation (Table 2). One of these 4 (UPN 9813)
may have been at higher risk of relapse because she had
high-risk cytogenetic abnormalities, close to 5% marrow
blasts pretransplantation, and received 10 Gy radiation expo-
sure. The other 3 patients who relapsed had no outstanding
features to suggest a higher risk of relapse. Following
Table 3. Posttransplantation Chimerism Studies for 14 Patients With Refractory Anemia Who Received the Modiﬁed CY/TBI Preparative Regimen*
Patient Chimerism Results: Day Posttransplantation, Percentage Donor Cells
Number Bone Marrow Whole Blood T Cells Granulocytes
8217 No data (death before engraftment) 
8315 Day 86: 100% Day 372: 100% Day 545: 50%† Day 545: 50%†
8454 Day 32: 99% Day 72: 97% 
8587 Day 328: 100% Day 1491: 100%, Day 1856: 100% 
8821 Day 91: 98.5%  Day 255: 94.8% Day 28: 95.8% 
Day 309: 77%‡
9075 Day 36: 95%§
9403 Day 75: 97% Day 95: 100% 
9589 Day 114: 99% Day 114: 98.5% Day 114: 99% 
No chimerism studies 
at relapse/death
9594 Day 80: 100% Day 448: 60%† Day 363: 95%, Day 398: 95%
9813 Day 29: 98% Day 74: 95% Day 157: 6.5%†  Day 32: 93.8%
10393 Day 29: 99.5% Day 57: 45%‡ Day 28: 99.5% 
10819 Day 109: 95% Day 430: 100%
10874 Day 32: 99.5% Day 79: 99% Day 28: 97%
10889 Day 32: 100% Day 80: 100% Day 365: 100%
*CY/TBI indicates cyclophosphamide/total body irradiation.
†Sample obtained at approximately the time that morphologic relapse was detected.
‡Sample obtained postmortem.
§Patient subsequently underwent high-dose immunosuppression and donor peripheral blood stem cell infusion because of pancytopenia
(ie, graft failure).
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relapse, 1 patient died of complications related to peripheral
cytopenias (UPN 9813), and another died of complications
related to acute leukemia (UPN 9589). Two relapsed patients
underwent a second BMT from the same donor as the ﬁrst
BMT, following a BU/CY preparative regimen. One of these
2 patients subsequently relapsed and died (UPN 8315), and
1 survives disease-free 16 months after this second BMT
(UPN 9594). Five patients are alive and well between 378
and 1856 days posttransplantation, without signs of MDS.
The outcome of these 14 cases was compared with the
outcome of 46 historical control cases in which standard
preparative regimens were used (as described in the Patients
and Methods section). In univariable analysis, the only signiﬁ-
cant difference between the patients in the historical and
experimental groups was patient age (Table 4). The 3-year
cumulative incidence of relapse was 34% versus 2% (P =
.0004), the cumulative incidence of nonrelapse mortality was
29% versus 37% (P = .8), and the actuarial DFS was 38% ver-
sus 61% (P = .16) in the experimental versus controls groups,
respectively (Figure). Because 4 of the patients older than
55 years in the experimental group received less than 12 Gy
TBI exposure and 1 TBI patient in the control group received
14 Gy, we made the same comparisons (incidences of nonre-
lapse mortality, relapse, and DFS) between the subsets com-
prising the 10 experimental patients who received 12 Gy and
the 45 historical control patients who received 12 Gy TBI or
BU/CY. There was no substantive difference in results for
this second comparison of patients (relapse rate of 33% versus
2%, P = .0009; nonrelapse mortality rate of 30% versus 38%,
P = .8; DFS rate of 38% versus 60%, P = .14) when compared
with results from the original experimental group. The exclu-
sion of the 4 patients older than 55 years demonstrated that
the relapse rate is high compared with that of a similarly age-
matched control population. Finally, we also performed a
subset analysis of patients receiving only TBI by comparing
the 14 patients in the experimental group with the 25 patients
in the control group who received only TBI. This subset
analysis further conﬁrmed our ﬁndings (relapse rate of 34%
versus 4%, P = .01; nonrelapse mortality rate of 29% versus
36%, P = .9; DFS rate of 38% versus 60%, P = .2).
DISCUSSION
The use of alloBMT for MDS is the established ther-
apy for young patients with suitable donors, with over
Table 4. Univariable Analysis of Clinical Characteristics and GVHD in 14
Patients With Refractory Anemia Who Received the Modiﬁed CY/TBI
Preparative Regimen Compared With 46 Historical Controls*
Variable Modified CY-TBI Controls P
Age (median), y 43 32.7 .0012
Disease duration 8 8 .9581 
(median), mos
Etiology†
Idiopathic 13 41 .68
Therapy-related 1 5
Cytogenetics†
Low-risk 9 24 .43
Intermediate-risk 4 10
High-risk 1 10
IPSS†
Low-risk 1 1 .141
Intermediate-1 13 34
Intermediate-2 0 9
Not done 0 2
HCT .6941
ANC .1701
Platelet Count .2276
Acute GVHD 46% 34% .7145
Chronic GVHD 27% 43% .3918
*GVHD indicates graft-versus-host disease; CY/TBI, cyclophos-
phamide/total body irradiation; IPSS, International Prognostic Scoring
System; HCT, hematocrit; ANC, absolute neutrophil count.
†Data are number of patients.
Cumulative incidence of nonrelapse mortality (A) and of relapse (B)
and actuarial disease-free survival (C) for 14 patients treated with mod-
iﬁed CY/TBI and 46 control patients treated with standard CY/TBI or
BU/CY. CY/TBI indicates total body irradiation– cyclophosphamide;
BU/CY, busulfan-cyclophosphamide.
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500 patients reported in the literature [9-19]. The first
3 patients with MDS who underwent alloBMT in Seattle
before 1981 were treated with the same preparative regimen
as patients with aplastic anemia [29]. This regimen, consist-
ing of CY only (200 mg/kg), was designed to be sufﬁciently
immunosuppressive to allow for donor engraftment, but was
not designed to be myeloablative, a clear distinction from
the CY/TBI regimen used for patients with leukemia. In all
3 of these initial patients, the neoplastic clone either per-
sisted or reemerged within 6 months posttransplantation
[29]. Subsequently, between 1981 and 1990, all patients with
MDS received CY/TBI as the preparative regimen [16].
Results from this study showed a striking difference in
relapse rates between patients with RAEB/RAEB-T (49%)
compared with patients with RA/refractory anemia with
ringed sideroblasts (RARS) (4%) [16,17]. Studies from other
transplant centers corroborate this very low rate of relapse
among patients with RA [9-15]. In an effort to reduce the high
nonrelapse mortality rate (43%) with CY/TBI, 30 patients
with RA were subsequently conditioned with a non-
irradiation–containing regimen of BU/CY between 1990
and 1993 [19]. In this study, we found that the substitution
of BU for TBI did not reduce nonrelapse mortality or
improve DFS, but of the 70 patients treated with either
CY/TBI or BU/CY, only 1 relapsed [19].
Transplantation-related toxicity following BU/CY or
CY/TBI (without organ shielding) includes respiratory fail-
ure and veno-occlusive disease of the liver, which can result
in ascites and renal dysfunction and thereby compromise
administration of GVHD prophylaxis [16,19]. We hypothe-
sized that selectively reducing radiation exposure to liver
and lungs might reduce organ toxicity and reduce GVHD,
because of improved compliance with GVHD prophylaxis.
Furthermore, we hypothesized that in RA patients, the neo-
plastic stem cell clone resides in the marrow or peripheral
blood, so that decreasing solid organ radiation exposure
would not compromise disease ablation. Therefore, in 1994,
we chose to study a novel preparative regimen consisting of
shielding the lungs and right lobe of the liver during TBI,
followed by administration of CY. However, after enrolling
14 patients, we closed the study early because 3 patients had
relapsed between 157 and 533 days posttransplantation.
Subsequent to study closure, a fourth patient relapsed. In
addition, 1 patient developed graft failure requiring subse-
quent high-dose immunosuppression and retransplantation
(UPN 9075), and 2 patients died with evidence of reemer-
gence of host hematopoiesis (UPN 8821 and 10393).
Because of early study closure, we were unable to test our
hypothesis that this preparative regimen would be associated
with lower regimen-related toxicity, GVHD, and nonrelapse
mortality compared with our standard regimens. However,
the similarity in nonrelapse mortality rates between treat-
ment and control groups (P = .8) suggests that shielding of
the right lobe of the liver and the lungs was not likely to
reduce nonrelapse mortality significantly compared with
conventional BU/CY or CY/TBI regiments.
The reason for the high incidence of relapse in this
study is not clear. Although an increased incidence of
relapse is documented with high-risk karytope [10], the
experimental and control groups had similar distributions of
cytogenetic risk. In addition, although 4 of 14 patients in
the experimental group received < 12 Gy TBI exposure and
were older than 55 years of age, analysis restricted to 12 Gy
TBI or BU/CY patients younger than 55 years showed simi-
lar results in the experimental and control groups. Historical
controls receiving BU/CY were speciﬁcally included in this
comparison because we have previously conclusively
demonstrated that there is no difference in relapse or nonre-
lapse mortality rates between patients receiving conven-
tional CY/TBI and BU/CY. Another factor to consider is
the role of a graft-versus-leukemia effect. Patients with
acute or chronic leukemia who develop GVHD may have a
lower incidence of relapse, presumably because of the con-
comitant graft-versus-leukemia effect of donor lymphocytes
[30]. However, the incidence of acute and chronic GVHD
in patients in this current study and in historical controls
was similar (Table 4), making this explanation unlikely. We
have also considered 3 factors that possibly contributed to
relapse. One factor is that although patients with signs of
extramedullary hematopoiesis were excluded, the shielded
tissues may have harbored neoplastic stem cells which
escaped myeloablation. The liver would be more likely to
harbor neoplastic stem cells than the lungs because the liver
is a common site for pathologic extramedullary hemato-
poiesis and because partial lung shielding during TBI, a
common practice at other centers, is not associated with an
increase in relapse risk. Another factor is the potential for
inadequate immunosuppression due to hilar and portal
hepatic lymph node shielding, which may have allowed for
secondary graft failure followed by reemergence of clonal
stem cells. A third factor is that patients in this study
received TBI before CY, whereas historical controls
received CY before unmodified TBI. This change in
sequence of agents was made for logistical reasons, so that
patients could receive radiation prior to admission to the
hospital for CY. These 3 factors are merely hypothetical,
and the available data cannot prove or refute them. If we
had performed serial chimerism studies of the T-cell and
myeloid compartments, we might have gained additional
insight into these possibilities.
There are several possible criticisms to the results and
conclusions of this study. First, this study does not address
the issue of whether patients with low- or intermediate-
1–risk MDS are best served by undergoing transplantation.
Such an issue can be addressed only by prospective studies of
transplantation versus no transplantation. Second, the
patients enrolled in this study included 2 patients who had
undergone prior transplantation for a preceeding disease.
However, 11% of the control population had therapy-related
MDS, a factor associated with an increased nonrelapse mor-
tality rate, but not an increased relapse rate compared with
patients with primary MDS [34]. Third, the study patients
were heterogeneous, including patients older than 55 years
and patients receiving various TBI exposure (including
1 dosimetry calculation error). However, even after exclud-
ing these patients, there was a higher incidence of relapse in
the study group compared with the control group.
In conclusion, we found that the cumulative incidence
of relapse for patients with RA receiving this modiﬁed TBI
regimen was clearly higher than in published data based on
similar patients who received conventional preparative
regimens [9-15,19,22]. Furthermore, although there are
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numerous problems with using institutional historical con-
trol patients, we found that the modiﬁed TBI regimen was
associated with a significantly higher incidence of relapse
than we had seen previously. Our goal in this phase II study
was to reduce toxicity without compromising efficacy of
alloBMT for RA so that this procedure would be more
widely applicable and successful. This goal is similar to that
of other regimens in which the intensity of the preparative
regimen is reduced, yet establishment of donor chimerism
and graft-versus-tumor effect is desired [31-33]. Our unex-
pected finding that shielding solid organs during TBI
increases the risk of relapse, without reducing the incidence
of GVHD, has significant implications for the other non-
myeloablative regimens. In the treatment of MDS, these
nonmyeloablative regimens may likely require careful moni-
toring and management of reemergence of host hemato-
poiesis to prevent high relapse rates.
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